Praxis Precision Medicines Inc
PRAXHealthcare|Biotechnology|USA
$323.81
-8.39 (-2.52%)
Tangible Book
$50.61
Earnings Power
$6.56
Upcoming Data Readouts (2)
Dec 2026
Est. completion
P3Developmental and Epileptic Encephalopathy 1
A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine
NCT07010471n=160
Jan 2027
Est. completion
P3Focal Epilepsy
Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures
NCT07505004n=300
Awaiting Results (1)
Trials past primary completion date but still active — data readout may be imminent.
Nov 2025
P2P3
A Clinical Trial of PRAX-562 in Subjects With Developmental and Epileptic Encephalopathies (DEE)
NCT05818553